4/30
02:08 pm
alpmy
Announcing More Customer Expansions [Yahoo! Finance]
Low
Report
Announcing More Customer Expansions [Yahoo! Finance]
4/23
07:35 pm
alpmy
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting [Yahoo! Finance]
Low
Report
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting [Yahoo! Finance]
4/23
07:30 pm
alpmy
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Low
Report
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
4/9
11:00 am
alpmy
Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery [Yahoo! Finance]
Low
Report
Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery [Yahoo! Finance]
4/4
01:00 pm
alpmy
First-of-its-kind non-hormonal treatment option now approved in Australia to reduce hot flushes and night sweats associated with menopause
Low
Report
First-of-its-kind non-hormonal treatment option now approved in Australia to reduce hot flushes and night sweats associated with menopause
3/28
11:00 am
alpmy
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Low
Report
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
3/26
08:42 am
alpmy
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy [Yahoo! Finance]
Low
Report
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy [Yahoo! Finance]
3/26
08:30 am
alpmy
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Low
Report
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
3/26
08:12 am
alpmy
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer [Yahoo! Finance]
Low
Report
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer [Yahoo! Finance]
3/26
08:00 am
alpmy
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Low
Report
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
3/22
08:13 am
alpmy
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting [Yahoo! Finance]
Low
Report
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting [Yahoo! Finance]
3/22
08:00 am
alpmy
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Low
Report
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
3/14
06:11 am
alpmy
HPE Asset Upcycling Services Selected by Astellas Pharma to Support Sustainability Commitments and Drive Network Standardization [Yahoo! Finance]
Low
Report
HPE Asset Upcycling Services Selected by Astellas Pharma to Support Sustainability Commitments and Drive Network Standardization [Yahoo! Finance]
3/11
09:00 am
alpmy
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Low
Report
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
3/5
08:50 am
alpmy
LabCentral and Astellas Launch Inaugural $500,000 "Diamond Ticket" at LabCentral 238 [Yahoo! Finance]
Low
Report
LabCentral and Astellas Launch Inaugural $500,000 "Diamond Ticket" at LabCentral 238 [Yahoo! Finance]
3/3
06:33 pm
alpmy
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan [Yahoo! Finance]
Low
Report
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan [Yahoo! Finance]
3/3
06:31 pm
alpmy
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
Low
Report
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
3/3
12:01 pm
alpmy
China welcomes Japanese business, Beijing's envoy Wu Jianghao says, trying to ease fears [Yahoo! Finance]
Low
Report
China welcomes Japanese business, Beijing's envoy Wu Jianghao says, trying to ease fears [Yahoo! Finance]
2/22
10:28 am
alpmy
Astellas Names Michael Petroutsas as Head of US Commercial [Yahoo! Finance]
Low
Report
Astellas Names Michael Petroutsas as Head of US Commercial [Yahoo! Finance]
2/22
10:15 am
alpmy
Astellas Names Michael Petroutsas as Head of US Commercial
Low
Report
Astellas Names Michael Petroutsas as Head of US Commercial
2/15
06:35 pm
alpmy
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics [Yahoo! Finance]
Low
Report
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics [Yahoo! Finance]
2/15
06:34 pm
alpmy
PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer [Yahoo! Finance]
Low
Report
PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer [Yahoo! Finance]
2/15
06:30 pm
alpmy
PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
Low
Report
PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
2/15
06:30 pm
alpmy
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
Low
Report
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
2/14
03:11 am
alpmy
Iktos opens a subsidiary in Japan and entrusts its management to Hideyoshi Fuji [Yahoo! Finance]
Low
Report
Iktos opens a subsidiary in Japan and entrusts its management to Hideyoshi Fuji [Yahoo! Finance]